MONTREAL, October 2, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented an updated, comprehensive technology overview of its nucleic acid polymer (NAP) technology at the Inaugural “Targeting HBV Symposium” at the 2017 Discovery on Target Meeting Held from September 25-29th in Boston, USA (http://www.discoveryontarget.com/Targeting-HBV/).
Replicor’s presentation gathered together all of the latest data on NAPs including:
- Chemistry of the NAP target interface.
- Mechanism of action of NAPs in HBV and HDV.
- The known biochemistry of subviral particle assembly and secretion and how NAPs are thought to affect this process.
- Preclinical toxicological and pharmacokinetic analysis of NAPs in mice and monkeys.
- Preclinical efficacy of NAPs in the duck model of HBV infection.
- An overview of the clinical data to date showing the well tolerated ability of NAPs to clear HBsAg in the majority of patients with HBeAg positive or negative chronic HBV infection and in patients with HBV / HDV co-infection.
- The unique ability of NAPs to potentiate the action of immunotherapy when serum HBsAg is <IU/mL.
This presentation can be downloaded at www.replicor.com/science/conference-presentations.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.